William Jordan, DO
Medical Oncology · Pagosa Springs, CONPI 1306898028
Payments from drug & device makers
Across 31 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$98
- Johnson & Johnson$85
- Merck$64
- Pfizer$51
- E.r. Squibb & Sons, L.L.C.$44
- Kyowa Kirin, Inc.$40
- plus $245 from 11 others
What the payments were for
- Food & beverage$57892%
- Education$498%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 2 | $98 |
| Johnson & Johnson | 5 | $85 |
| Merck | 3 | $64 |
| Pfizer | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Kyowa Kirin, Inc. | 2 | $40 |
| Bristol Myers Squibb | 2 | $37 |
| Novartis | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $24 |
| AstraZeneca | 1 | $21 |
| AbbVie | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Novocure Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
| Verastem, Inc. | 1 | $12 |
How this compares
$627 in reported general payments places this provider in the 25th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 11 | $126,709 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Pagosa Springs
- Gerald FalchookDenver$16.1M
- Karl LewisAurora$12.4M
- Christopher LieuAurora$8M
- David CamidgeAurora$7.3M
- Theresa MedinaAurora$7M
- Wells MessersmithAurora$6.3M
- Antonio JimenoAurora$5.6M
- Elizabeth KesslerAurora$5.1M
- Sarah DavisAurora$3.9M
- Sunnie KimAurora$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.